证券代码：002940 证券简称：昂利康 公告编号：2025-058 浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 4、经核查，公司及控股股东、实际控制人不存在关于本公司的应披露而未 披露的重大事项，也不存在处于筹划阶段的重大事项； 5、经核查，公司控股股东和实际控制人在股票交易异常波动期间不存在买 卖公司股票的行为； 6、公司关注到近期市场对创新药业务关注度较高。公司目前在研的创新药 项目仅有一个，系 ALK-N001 项目，该项目于 2025 年 4 月获得药物临床试验批 一、股票交易异常波动的情况介绍 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 2 个交易日（2025 年 7 月 31 日、2025 年 8 月 1 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规 则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如 ...

Core Viewpoint - The company has approved a share repurchase plan to buy back a portion of its publicly issued shares using its own funds and a special loan, with a total repurchase amount between RMB 50 million and RMB 70 million, and a maximum price of RMB 21.07 per share [1] Group 1: Share Repurchase Plan - The company plans to use its own funds and a special loan to repurchase shares, with a total amount not less than RMB 50 million and not exceeding RMB 70 million [1] - The repurchase price will not exceed RMB 21.07 per share, and the actual number of shares repurchased will depend on the execution [1] - The implementation period for the repurchase is set for up to 12 months from the board's approval date [1] Group 2: Progress of Repurchase - As of July 31, 2025, the company has repurchased a total of 3,599,700 shares, accounting for approximately 1.78% of the total share capital [2] - The highest transaction price during the repurchase was RMB 17.00 per share, while the lowest was RMB 12.17 per share, with a total transaction amount of RMB 50,001,275.28 (excluding transaction fees) [2] Group 3: Compliance and Regulations - The company has adhered to the regulations set forth by the Shenzhen Stock Exchange regarding share repurchase, including not repurchasing during significant events that could impact share prices [3] - The repurchase transactions comply with the requirements that the entrusted price must not exceed the daily trading limit and must not occur during specific trading periods [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]

Market Overview - On the first trading day of August, the A-share market experienced overall weakness, with major sectors such as oil and petrochemicals, semiconductors, and non-bank financials adjusting, leading to declines in the three major stock indices [2] - The Shanghai Composite Index closed at 3559.95 points, down 0.37%; the Shenzhen Component Index closed at 10991.32 points, down 0.17%; and the ChiNext Index closed at 2322.63 points, down 0.24% [2] - The total trading volume in the Shanghai and Shenzhen markets was 15,983 billion yuan, a decrease of over 3,300 billion yuan compared to the previous trading day [2] Solar Equipment Sector - The solar equipment sector showed strong performance, with the Shenwan Solar Equipment Index closing up 2.60%, leading all secondary industries [3] - Companies such as Jiejia Weichuang and Shuangliang Energy reached the daily limit [3] - The Ministry of Industry and Information Technology recently issued a special energy-saving inspection task list for the polysilicon industry for 2025, requiring local authorities to implement and report results by September 30 [3] - According to China International Capital Corporation (CICC), this move is aimed at optimizing the supply side of the industry and may lead to the exit of backward production capacity, particularly affecting the upstream polysilicon segment [3] Express Delivery Sector - The express delivery sector also performed actively, with the Shenwan Logistics Index rising by 1.53% [3] - Companies such as YTO Express, Shentong Express, and Yunda Holdings saw increases of over 6%, while other stocks like Debang Logistics also followed suit [3] - On July 29, the State Post Bureau held a meeting with express delivery companies to address issues related to "involution" competition and promote high-quality industry development [4] Innovative Drug Sector - The innovative drug sector remained active, with stocks like Weikang Pharmaceutical hitting a 20% daily limit, and companies such as Anglikang and Guizhou Bailin recording consecutive gains [5] - Recent announcements from companies like Haizike and Huahai Pharmaceutical regarding new drug applications have contributed to the sector's momentum [5] - According to Dongfang Securities, the global innovative drug field is shifting from "Made in China" to "Created in China," with domestic pharmaceutical companies enhancing their international competitiveness [5] Dividend and Resource Sectors - Looking ahead to August, the strategy team at Industrial Securities suggests focusing on dividend sectors and resource industries for investment opportunities [6] - Historical data indicates that the first half of August typically sees fewer companies disclosing semi-annual results, leading to a higher success rate for small-cap stocks [6] - As the month progresses and companies begin to report earnings, larger-cap stocks with earnings certainty are expected to gain more attention, particularly in resource sectors like coal and petrochemicals [6]

证券日报网讯8月1日晚间，昂利康（002940）发布公告称，截至2025年7月31日，公司通过回购专用证 券账户以集中竞价交易方式累计回购股份数量为3，599，700股，约占公司总股本的1.78%。 ...

Core Viewpoint - The recent approval of new drug formulations by Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Anglikang") highlights the company's strong drug development capabilities and strategic shift towards innovative drugs, which is expected to enhance its market position and revenue growth. Group 1: Recent Approvals and Product Pipeline - Anglikang received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets, classified as a Class 3 chemical drug, which is intended for adult patients with type 2 diabetes [1] - In addition to the Sitagliptin Metformin, Anglikang has also received approvals for Amlodipine Besylate Tablets (5mg, 10mg) and Methocarbamol Injection, expanding its product offerings in hypertension and acute muscle pain treatments [1] - The recent approvals indicate Anglikang's effective execution in drug development, clinical trials, and registration processes, showcasing its robust research capabilities [1] Group 2: Strategic Transformation and Innovation - Anglikang is transitioning from a focus on generic drugs to a strategy that emphasizes both generics and innovative drugs, achieving significant breakthroughs in the innovative drug sector [2] - The company has developed ALK-N001, a globally innovative small molecule conjugate drug for tumor microenvironment activation, which has received clinical trial approval, potentially offering new treatment options for advanced solid tumor patients [2] - Successful commercialization of innovative drugs could significantly enhance Anglikang's economic benefits and core competitiveness, positioning the company favorably in future market competition [2] Group 3: Exploration of New Markets - Anglikang is actively exploring the pet medicine sector, with multiple products expected to receive approval by the end of 2024 and several new veterinary drugs entering clinical trials [2] - The exploration of innovative and pet medicine sectors is anticipated to optimize Anglikang's existing product structure and attract more investment opportunities, supporting stable growth in both domestic and international markets [2]

Core Insights - On August 1, institutional investors showed significant activity in the stock market, with a total of 38 stocks being involved, of which 18 experienced net buying and 20 faced net selling [1][2]. Group 1: Institutional Net Buying - The top three stocks with the highest net buying by institutions were Anglikang, Tianfu Culture Tourism, and Shen Sanda A, with net buying amounts of 186 million, 152 million, and 104 million respectively [1][2]. - Other notable stocks with institutional net buying included Asia-Pacific Pharmaceutical (10,215.46 million), New Henghui (7,762.80 million), and Huason Pharmaceutical (4,635.90 million) [2]. Group 2: Institutional Net Selling - The top three stocks with the highest net selling by institutions were Beifang Changlong, Kechuan Technology, and Jinling Sports, with net selling amounts of 108 million, 72.88 million, and 35.16 million respectively [1][3]. - Additional stocks that faced significant net selling included Shunlian Biotech (1,968.76 million), Ruikeda (2,306.42 million), and Jinyang Sports (3,515.56 million) [3].

格隆汇8月1日丨昂利康(002940.SZ)公布，截至2025年7月31日，公司通过回购专用证券账户以集中竞价 交易方式累计回购股份数量为3,599,700股，约占公司总股本的1.78%，最高成交价为17.00元/股，最低 成交价为12.17元/股，交易总金额5000.13万元(不含交易费用)。 ...

1、公司未在下列期间回购股份： 证券代码：002940 证券简称：昂利康 公告编号：2025-057 浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到< ...

Market Overview - The A-share market experienced a technical adjustment with all three major indices slightly declining, reflecting a market structure that necessitates a pullback after rapid gains [2][9] - The Shanghai Composite Index fell by 0.37%, the Shenzhen Component Index by 0.17%, and the ChiNext Index by 0.24%, with over 3,300 stocks rising throughout the market [1][2] Sector Performance - The pharmaceutical sector showed resilience, with companies like Angli Kang (002940) and Weikang Pharmaceutical (300878) hitting the daily limit [1] - The photovoltaic sector rebounded, supported by regulatory measures aimed at enhancing energy efficiency in the polysilicon industry, leading to price stabilization across the supply chain [3] - The logistics and express delivery sector strengthened due to recent regulatory discussions aimed at promoting high-quality development and addressing competitive issues [4] Investment Trends - The innovation drug sector continues to thrive, with a positive outlook for Chinese innovative drugs entering international markets, although short-term volatility may increase [5] - Financing balance in A-shares reached a ten-year high of 1.971 trillion yuan, indicating strong market risk appetite, with net purchases exceeding 130 billion yuan in July [6][7] - A significant portion of the financing activity was concentrated in the pharmaceutical, electronics, and non-ferrous metals sectors, with notable net purchases [7][8] Future Outlook - Analysts suggest that despite the current technical adjustments, the medium-term upward trend in A-shares remains intact, with average P/E ratios indicating a favorable environment for long-term investments [9] - Investment strategies should focus on high-growth technology sectors, industries with strong earnings support, and potential opportunities arising from policy changes [10]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002940 | 昂利康 | 62.92 | 10.00% | 11.62万 | 7.17亿 | | 601089 | 福元医药 | 26.54 | 9.99% | 10.13万 | 2.68 亿 | | 600774 | 汉商集团 | 12.46 | 9.97% | 31.00万 | 3.72亿 | | 002370 | 亚太药业 | 7.40 | 9.96% | 309.35万 | 22.01亿 | | 002437 | 营衡药业 | 4.04 | 8.89% | 482.38万 | 19.13 Z | | 300966 | 并同药业 | 26.68 | 8.41% | 29.78万 | 8.08亿 | | 688658 | 倪康药业 | 33.79 | 7.82% | 16.60万 | 5.72亿 | | 688091 | 上海谊众 | 77.63 | 7.79% | 12.47万 | 9.36 Z | | 600513 | 联环药业 | 4 ...